fbpx

molecules of the month

TDI-11861

oral sAC inhibitor

intended for male contraception

opt. from TDI-10229 + SBDD

J. Med. Chem., 08 November 2022

Tri-I TDI/Weill Cornell Medicine, New York, NY

TDI-11861 chemical structure oral sAC inhibitor- Tri-I TDI/Weill Cornell Medicine, New York, NY
4 mins read

sAC as a target for male contraception. Soluble adenylyl cyclase (sAC) is one of several ACs that catalyze the cyclization of ATP to form cyclic adenosine monophosphate (cAMP). cAMP is the second messenger in several signaling pathways including that which activates sperm to be capable of fertilizing eggs (“capacitation”). The target is genetically validated in humans, as two adult human males were recently diagnosed with infertility due to a sAC mutation that rendered their sperm immotile. sAC inhibitors such as TDI-11861 could be effective as on-demand, non-hormonal male contraceptives, a longstanding unmet medical need. Drug target residence time as a key property requirement. sAC is regulated by changes in cellular bicarbonate levels. Sperm are stored under low bicarbonate conditions (<5…


request a trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.

Interested in learning more? Submit this form to request a trial.


already a member? log in: